Immune Response of People Living with HIV to COVID-19
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 222
Special Issue Editors
Interests: nosocomial infections; antimicrobial resistance mechanisms; HIV immunology; SARS-CoV-2 infection
Special Issues, Collections and Topics in MDPI journals
Interests: vaccine-preventable diseases; influenza; healthcare personnel; occupational; healthcare-associated infection
Special Issues, Collections and Topics in MDPI journals
Interests: nosocomial infections; antimicrobial resistance mechanisms; HIV immunology; SARS-CoV-2 infection
Special Issue Information
Dear Colleagues,
More than two years into the COVID-19 pandemic, significant success has been recorded in research, mainly in relation to prevention of the disease. However, many questions remain regarding our understanding of the immune response following natural infection and vaccination. For people living with HIV (PLWH) who experience SARS-CoV-2, limited evidence suggests a lower magnitude of humoral and cell-mediated immune responses and a shorter-duration antibody response compared to HIV-naïve individuals. Moreover, further study is needed to elucidate the immune response following vaccination among the PLWH population, since sparse data exist on the immunogenicity of non-replicating adenovirus vector, messenger RNA, or protein-based COVID-19 vaccines in PLWH. Suboptimal responses to immunization against other infections such as yellow fever, hepatitis B, influenza, polio, diphtheria, and tetanus among PLWH were also reported.
The focus of this Special Issue is on recent advances in the understanding of the host immune responses following natural infection and vaccination, as well as the immunologic processes resulting in post-acute sequelae of SARS-CoV-2 infection among PLWH. Adding new information on this population is expected to improve our knowledge of the immune response towards SARS-CoV-2 among PLWH and aid in tailored prevention and treatment modalities against COVID-19.
Dr. Lemonia Skoura
Dr. Helena C. Maltezou
Dr. Giota Lourida
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- vaccination in immunocompromised
- immune response
- HIV
- COVID-19
